Canada markets closed
  • S&P/TSX

    21,357.56
    +64.56 (+0.30%)
     
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • DOW

    35,911.81
    -201.79 (-0.56%)
     
  • CAD/USD

    0.7971
    +0.0005 (+0.06%)
     
  • CRUDE OIL

    84.47
    +0.65 (+0.78%)
     
  • BTC-CAD

    53,934.12
    -491.96 (-0.90%)
     
  • CMC Crypto 200

    1,036.02
    +10.29 (+1.00%)
     
  • GOLD FUTURES

    1,815.10
    -1.40 (-0.08%)
     
  • RUSSELL 2000

    2,162.46
    +3.02 (+0.14%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • NASDAQ

    14,893.75
    +86.95 (+0.59%)
     
  • VOLATILITY

    19.19
    -1.12 (-5.51%)
     
  • FTSE

    7,542.95
    -20.90 (-0.28%)
     
  • NIKKEI 225

    28,402.40
    +278.12 (+0.99%)
     
  • CAD/EUR

    0.6984
    +0.0009 (+0.13%)
     

EXICURE ALERT: Bragar Eagel & Squire, P.C. is Investigating Exicure, Inc. on Behalf of Exicure Stockholders and Encourages Investors to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Nov. 27, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) on behalf of Exicure stockholders. Our investigation concerns whether Exicure has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On November 15, 2021, after market hours, Exicure filed a Form 12b-25 with the U.S. Securities and Exchange Commission (SEC) stating that it could not timely file its quarterly report for the period ended September 30, 2021. Exicure stated that it "has retained external counsel to conduct an internal investigation” regarding "a claim made by a former Company senior researcher regarding alleged improprieties that researcher claims to have committed with respect to the Company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia.”

On this news, Exicure’s share price fell $0.293, or 27%, to close at $0.777 per share on November 16, 2021, the next trading day, on heavy trading volume.

If you purchased or otherwise acquired Exicure shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra B. Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting